• Link zu LinkedIn
  • Link zu Instagram
  • Link zu Youtube
Saxocell
  • Startseite
  • Über uns
    • Unser Team
    • Unsere Partner
  • Forschung
    • Publikationen
  • Events
    • News & Presse
  • Transfer
    • Patente
  • SaxoCell Konferenz
  • SaxoCell e.V.
  • Members Login
  • Newsletter
  • English
  • Click to open the search input field Click to open the search input field Suche
  • Menü Menü
50 Veranstaltungen gefunden.

Veranstaltungen

Veranstaltungen Suche und Ansichten, Navigation

Veranstaltung Ansichten-Navigation

  • Liste
  • Monat
  • Tag
Heute
  • März 2024

  • Di. 19

    Clusterkonferenz 2024 – Innovative Medizin in NRW

    19. März 2024
    Düsseldorf, Germany

    Organiser: Cluster Medizin.NRW

  • Mi. 27

    SaxoCell FuckUpNight – Failure, Fun and the Future

    27. März 2024 @ 18:30 - 20:30 CET
    Dresden, Germany

    Location: COSMO Wissenschaftsforum im Kulturpalast Dresden Guests: Anne-Kristin Heninger (Seamless Therapeutics) und Matthias Hebrok (TU Munich)

  • April 2024

  • Mi. 10

    Der Weg zu erfolgreichen Schutzrechtsanmeldun­gen – Teil I – Technische Schutzrechte (Patente und Gebrauchsmuster)

    10. April 2024 @ 14:00 - 17:00 CEST
    Online

    Online event

  • Di. 16

    Deutsche Biotechnologietage 2024

    16. April 2024 - 17. April 2024
    Berlin, Germany
  • Mi. 17

    Der Weg zu erfolgreichen Schutzrechtsanmeldun­gen – Teil II – Patentrecherchen

    17. April 2024 @ 14:00 - 17:00 CEST
    Online

    Online event

  • Di. 23

    Neue immunologische Tumortherapien: Die überraschende Revolution – Mit dem Immunsystem den Krebs bekämpfen

    23. April 2024 @ 10:30 - 11:30 CEST
    Leipzig, Germany

    Location: University Leipzig, BBZ, Seminar room 1 (auditorium) Speakers: - Prof. Dr. Gottfried Alber (Institute of Immunology at the Faculty of Veterinary Medicine, UL) - Prof. Dr. Dr. Christine E. Engeland (Medical Clinic I of the Medical Faculty, UL) - Dr. Andreas Grahnert (Fraunhofer Institute for Cell Therapy and Immunology IZI)

  • Di. 23

    Flow Cytometry Workshop

    23. April 2024 @ 10:30 - 14:30 CEST
    Hybrid

    Host: Fraunhofer IZI Advanced Analytics Technology Platform Agenda: 10:30 AM - 12:00 PM: Lecture „Flow Cytometry Basics“ 12:00 PM - 1:00 PM: Lunch break 1:00 PM - 2:00 PM: Short presentations: Introduction CytoFLEX flow cytometer, Infinicyte Software and Kaluza Software 2:00 PM - 2:30 PM: Q&A, Discussion Teams Besprechungs-ID: 394 486 196 456 Passcode: kN8ZjH […]

  • Di. 23

    Schutz von Innovationen in einer sich schnell wandelnden Welt

    23. April 2024 @ 13:00 - 17:00 CEST
    Dresden, Germany

    Host: Patentinformationszentrum (PIZ) Dresden (TUD|excite) Location: Open Science Lab 2, SLUB, Zellescher Weg 25, 01217 Dresden, 1. Etage Agenda: 13:00 - 13:15 Uhr: Begrüßungswort 13:15 - 14:00 Uhr: IP-Strategie im Unternehmen Wie können wir die Mittel des Gewerblichen Rechtsschutzes zum Erfolg unseres Unternehmens einsetzen? Peter Adler, Patentanwalt, Kanzlei LIPPERT STACHOW Patentanwälte Rechtsanwälte Partnerschaft mbB 14:00 […]

  • Mi. 24

    Der Weg zu erfolgreichen Schutzrechtsanmeldungen – Teil III – Nichttechnische Schutzrechte (Marken und Designs)

    24. April 2024 @ 13:30 - 17:30 CEST
    Online

    Online event

  • Mo. 29

    Evaluating Antigen Specificity and its Impact on Immunity using Dextramer® Technology

    29. April 2024 @ 15:00 - 16:00 CEST
    Online

    Speaker: Matilda Weywadt (PhD and Global Product Manager at Immudex) Online link will follow

  • Mai 2024

  • Do. 2

    SaxoCell Pitch-Training

    2. Mai 2024 - 3. Mai 2024
    Dresden, Germany

    In preparation of SaxoCell Retreat 2024 May 2: in presence in Dresden (CRTD) May 3: online from 9 AM to 5 PM

  • Di. 14

    Eat & Talk Startup Förderung – Von der Idee zum Investment

    14. Mai 2024 @ 9:00 - 11:00 CEST
    Leipzig, Germany

    Breakfast round table with start-up expert René Preusche (Sächsische Aufbaubank - SAB) Location: main building of SAB in Leipzig (Gerberstraße 5, 04105 Leipzig)

  • Di. 14

    Grundlagen des Markenschutzes: Nationale und europäische Perspektiven

    14. Mai 2024 @ 15:00 - 16:00 CEST
    Online

    Organiser: HGF Europe LLP Partner: BVIZ Registration required!

  • Fr. 17

    SaxoCell Spark Meeting – Regarding ATMP production

    17. Mai 2024 @ 11:00 - 12:30 CEST
    Online

    Speakers: Mirko Müller, Lilly Stahl, Torsten Tonn Zoom meeting

  • Di. 21

    SaxoCell Patientennachmittag

    21. Mai 2024 @ 15:30 - 19:00 CEST
    Leipzig, Germany

    Lebende Arzneimittel: Ein Nachmittag für Blutkrebspatienten in Leipzig Location: Medizinisches Forschungszentrum, Hörsaal C, Liebigstr. 21, 04104 Leipzig

  • Do. 23

    SaxoCell Jury Site Inspection

    23. Mai 2024 @ 10:00 - 17:00 CEST
    Dresden, Germany

    Location: CRTD, Fetscherstraße 105, 01307 Dresden With representatives from BMBF and PTJ

  • Di. 28

    Lunch Meeting „Dextramer® Technologies: Advancing Immune Cell Analysis and Beyond“

    28. Mai 2024 @ 13:00 - 14:00 CEST
    Online

    Presenter: Valérie Bodemeyer (PhD and Technical Application Manager Immudex) and Mohammad Salem (PhD and Senior Pharma Business & Solution Manager Immudex) This webinar will explore how Dextramer® technology can support the development of more potent and effective cell-based therapies. Discussion topics: - Introduction to Dextramer® technology and its application in immune cell detection and characterization […]

  • Di. 28

    Miltenyi seminar series “From target validation to clinical application” – Ultra High Content Imaging with the MACSimaTM Platform

    28. Mai 2024 @ 14:00 - 16:00 CEST
    Dresden, Germany

    Live in Dresden & via MS Teams Location: Seminar room 1 at MTZ/Haus 91 (Fiedlerstraße 42, 01307 Dresden) Identification and validation of molecular targets build the basis for each targeted cellular therapy. In our first seminar we will talk about the potential of Spatial Biology for target identification and validation as well as possibilities for […]

  • Di. 28

    Dresden Translational Oncology Seminar (DTOS) Series – Mechanisms of resistance to CAR-T cell therapies

    28. Mai 2024 @ 17:00 - 18:00 CEST
    Hybrid

    Host: Martin Bornhäuser Speaker: Dr. Reuben Benjamin (King’s College London) Location: UKD H66 conference room and Zoom

  • Juni 2024

  • Mo. 3

    BERD Data Marketplace: Fostering Academia-Industry Collaboration

    3. Juni 2024 @ 16:00 - 17:00 CEST
    Online

    Speaker: Prof. Dr. Florian Stahl (Speaker of BERD@NFDI) About the talk: In the era of data-driven decision making and data monetization, the Business, Economic and Related Data (BERD) initiative at NFDI has established an innovative Data Marketplace to facilitate collaborations between academic researchers and industry. This platform serves needs of both sides for sharing and […]

  • Di. 4

    Retreat 2024

    4. Juni 2024 - 5. Juni 2024
    Chemnitz, Germany

    Location: Congress Hotel Chemnitz Deadline for registration: 21 May 2024

  • Di. 11

    Alternatives to Animal Testing 2024

    11. Juni 2024 @ 9:00 - 18:00 CEST
    Hanover, Germany

    In cooperation with Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD Location: CRC Hannover - Clinical Research Center Hannover Workshop language: English

  • Di. 11

    Dresden Translational Oncology Seminar (DTOS) Series – T-cell targeted gene vectors for in vivo applications in cancer immunotherapy

    11. Juni 2024 @ 17:00 - 18:00 CEST
    Online

    Host: Martin Bornhäuser Speaker: Prof. Christian Buchholz, PEI

  • Do. 13

    Der Goldhamster als Versuchstier

    13. Juni 2024 @ 13:00 - 14:00 CEST
    Leipzig, Germany

    Speaker: Dr. Stefanie Perl Location: Fraunhofer IZI Leipzig (room Dresden) About the lecture: With the corona pandemic and the associated research, hamsters have gained enormously in importance in a scientific context. However, due to their biological and physiological characteristics, breeding and keeping these small rodents in research facilities is associated with a number of challenges. […]

  • Do. 13

    Expanding the T cell immunotherapy toolbox with oncolytic viruses and mathematics

    13. Juni 2024 @ 17:00 - 18:30 CEST
    Leipzig, Germany

    Speaker: Dr. Johannes Heidbüchel (DKFZ) Location: Johannisallee 21 (Institute of Biology), room: Kleiner Hörsaal (119)

  • Fr. 14

    Long Night of Science Dresden 2024

    14. Juni 2024 @ 17:00 - 23:00 CEST
    Dresden, Germany

    Find SaxoCell on the ground floor at the bottom of the staircase! Like last year, we will be offering our immune cell quiz and fishing game. And as always we look forward to interesting discussions.

  • Di. 18

    72. Life Science Stammtisch „Künstliche Intelligenz in der Biotechnologie“

    18. Juni 2024 @ 17:00 - 19:00 CEST
    Leipzig, Germany

    Organiser: biosaxony, AGIL GmbH Leipzig, IHK Leipzig Location: Fraunhofer IZI, Perlickstr. 1, 04103 Leipzig Registration required!

  • Mi. 19

    Sächsische Innovationskonferenz 2024

    19. Juni 2024
    Dresden, Germany

    Location: Airport Dresden

  • Mi. 26

    Miltenyi seminar series “From target validation to clinical application” – Engineered T Cells: Rue to GMP

    26. Juni 2024 @ 14:00 - 16:00 CEST
    Leipzig, Germany

    Live in Leipzig & via MS Teams Location: tba Identification and validation of molecular targets build the basis for each targeted cellular therapy. In our first seminar we will talk about the potential of Spatial Biology for target identification and validation as well as possibilities for patient stratification using the MACSima Platform. The talks will […]

  • Mi. 26

    Tagesspiegel Fachforum Gesundheitswirtschaft

    26. Juni 2024 @ 15:00 - 17:30 CEST
    Hybrid

    Topic: Land, Bund, Leuchtturm: Wie gelingt der Umschwung in der Gesundheitswirtschaft? Location: Verlagshaus am Askanischen Platz in Berlin or live stream Registration required!

  • Juli 2024

  • Di. 2

    Good Scientific Practice Workshop for SaxoCell PhD students and Postdocs

    2. Juli 2024 @ 9:00 - 3. Juli 2024 @ 17:00 CEST
    Online

    Online course by Dr. Andrea Kliewer Institute for Pharmacology and Toxicology Jena University Hospital Course duration: 1.5 days max. 14 participants

  • Do. 25

    Tissue networks of macrophages in skin during wound healing

    25. Juli 2024 @ 17:00 - 18:00 CEST
    Leipzig, Germany

    Colloquium of the Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics Lecturer: Sandra Franz Location: Leipzig University Hospital, House 4 (Room Justus von Liebig)

  • August 2024

  • Mi. 7

    biosaxony Lunch Session – Offene Märkte, Offene Gesellschaften: Die Bedeutung von Demokratie und Weltoffenheit

    7. August 2024 @ 12:30 - 14:00 CEST
    Online
  • Sa. 10

    MS-Tag 2024

    10. August 2024 @ 10:00 - 14:00 CEST
    Dresden, Germany

    at CRTD

  • Mo. 19

    SaxoCell Compliance Workshop

    19. August 2024 @ 9:00 - 16:00 CEST
    Online

    Speaker: Prof. Dr. Andreas Kark (compliance consultancy Prof. Dr. Andreas Kark) Zoom link will be provided.

  • So. 25

    International Excite Summer School „Patents in search of business“

    25. August 2024 - 31. August 2024
    Hoyerswerda, Germany

    Scientists and economists working together to develop utilisation concepts for existing IP Organiser: TUD|excite Registration deadline: 30 June

  • Di. 27

    Miltenyi seminar series “From target validation to clinical application” – (Allogenic) CAR NK Cells: From Bench to Bedside

    27. August 2024 @ 14:00 - 16:00 CEST
    Leipzig, Germany

    Live in Leipzig & via MS Teams Location: Fraunhofer IZI Identification and validation of molecular targets build the basis for each targeted cellular therapy. In our first seminar we will talk about the potential of Spatial Biology for target identification and validation as well as possibilities for patient stratification using the MACSima Platform. The talks […]

  • Di. 27

    SaxoCell Stammtisch

    27. August 2024 @ 17:30 - 19:30 CEST
    Dresden, Germany

    Location: CRTD

  • Mi. 28

    Cytiva UserDay – ÄKTA systems plus Imaging und Biacore systems

    28. August 2024 - 29. August 2024
    Leipzig, Germany

    Location: Fraunhofer IZI, Perlickstr. 1, 04103 Leipzig Registration required!

  • Mi. 28

    Cytiva User Day @ Fraunhofer IZI

    28. August 2024 - 29. August 2024
    Leipzig, Germany

    Location: Fraunhofer IZI The spotlight will be on adeno-associated virus (AAV) and protein production and equipment: ÄKTA™ systems plus imaging and Biacore™ systems. Engage in scientific presentations, hands-on sessions with Cytiva equipment, and take the opportunity to take a tour through the institute.

  • Do. 29

    Dornburg Cancer Talks

    29. August 2024 @ 9:00 - 18:00 CEST

    Forum for young scientists in the field of oncology Dornburg Cancer Talks is a joint scientific meeting of the Comprehensive Cancer Center Central Germany and the Institute of Molecular Cell Biology addressing doctoral fellows and early postdocs from the field of oncology to present their projects in oral communications or as posters. Discussions with other […]

  • Sa. 31

    Informationstag Krebs

    31. August 2024 @ 13:00 - 18:00 CEST
    Leipzig, Germany

    Hybrid Location: Uniklinik Leipzig, Hörsaal Haus 4

  • September 2024

  • Di. 3

    Miltenyi seminar series “From target validation to clinical application” – Hands-on workshop on the Prodigy

    3. September 2024
    Leipzig, Germany

    Location: Fraunhofer IZI Leipzig, Perlickstr. 1 With ten years on the market, the CliniMACS Prodigy is a well-established state-of-the-art platform for automated cell processing. It constantly evolves for meeting new requirements in T cell- or NK cell engineering approaches in the field.

  • Do. 5

    Cross clustering event with Proxidrugs

    5. September 2024 @ 12:00 - 6. September 2024 @ 13:00 CEST
    Erfurt, Germany

    Strategic exchange with Clusters4Future Proxidrugs on innovative therapies for human diseases: Targeted degradation as a new mode of action for drugs Participants: SaxoCell speakers and Hub representatives

  • Mo. 9

    6. ForTra Translatorik-Workshop: „Financing and manufacturing – important things to consider to propel your project from lab to clinic“

    9. September 2024 - 10. September 2024
    Frankfurt, Germany

    Organiser: Else Kröner-Fresenius-Stiftung

  • Mo. 9

    Lumicks Lunch Meeting

    9. September 2024 @ 12:00 - 13:00 CEST
    Online

    In a live webinar on “Cell Avidity: Understanding the mechanism of action through cell-cell binding”! Rogier Reijmers (Principal Scientist) will show you how cell avidity measurements are essential to understand cellular mechanisms. To get the dial-in link, please register!

  • Mo. 16

    SaxoCell IP-Workshop

    16. September 2024 - 17. September 2024
    Dresden, Germany

    Location: Zellescher Weg 21, 01217 Dresden Day 1 - 16/09/2024, start: 9 am, end: 5 pm Introduction to the topic of "Industrial property rights" (focus on technical property rights, especially patents) - From scientific manuscript to patent: structure of a patent specification, creation/construction of a patent specification (classification, generic term, organisation of claims, etc.); delimitation […]

  • Di. 17

    3. Erfahrungsaustausch der BMBF-Zukunftscluster

    17. September 2024 @ 12:00 - 18. September 2024 @ 13:00 CEST
    Munich, Germany

    1st day: CNATM - LMU München CNATM @ LMU, Institut für Chemische Epigenetik – ICEM, Ludwig-Maximilians-Universität München, Würmtalstr. 201, 81377 München 2nd day: MCube - TU München Münchner Cluster für die Zukunft der Mobilität in Metropolregionen (MCube), Vorhoelzer Forum, TUM, Arcisstr. 21, 80333 München SaxoCell representatives: Stefanie Binder Frank Buchholz Maren Henneken Ulrike Köhl

  • Do. 19

    Talk „Medical Data Science: Trends and Perspectives“

    19. September 2024 @ 14:00 - 15:00 CEST
    Hybrid

    Speaker: Dr. Holger Hennig (Head of Innovation Area Medical Data Science at Fraunhofer Institute for Translational Medicine and Pharmacology ITMP) Location: Frauinhofer IZI, Perlickstraße 1, 04103 Leipzig (Room Deutschland/Sachsen, Leipzig)

  • Di. 24

    Prague.bio Conference 2024

    24. September 2024
    Prague, Czech Republic

    Biotech conference for start-ups, pharma and diagnostic companies, investors, researchers, and other biotech experts from Central Europe.

  • Vorherige Veranstaltungen
  • Heute
  • Nächste Veranstaltungen
  • Google Kalender
  • iCalendar
  • Outlook 365
  • Outlook Live
  • .ics-Datei exportieren
  • Exportiere Outlook .ics Datei

Präzisionstherapie-Cluster

SaxoCell Logo

Weitere Informationen

  • Kontakt
  • Impressum
  • Datenschutzerklärung
  • Barrierefreiheit (dt)
  • Accessibility (eng)
Nach oben scrollen Nach oben scrollen Nach oben scrollen

Neuer Ansatz gegen solide Tumore: EU investiert 2,5 Millionen Euro in innovative Krebstherapie an der TU Dresden

Magdalena Gonciarz, Zentrum für Regenerative Therapien Dresden (CRTD)

Gruppenfoto von Michael Sieweke, Anke Fuchs und Angela Jacobi vor einem petrolfarbenen Hintergrund. Alle lächeln freundlich in die Kamera und halten gemeinsam ein stilisiertes Modell einer Makrophage in den Händen, also jener Immunzelle, die im Zentrum des neuen Therapieansatzes steht.
Das EliaCell Leitungsteam: Prof. Michael Sieweke, Dr. Anke Fuchs und Dr. Angela Jacobi.
© Martin Kaßner

Der Europäische Innovationsrat (EIC) fördert das Projekt „StemPhage“ mit 2,5 Millionen Euro. Das Projekt führt die immunologische Forschung von Prof. Michael Sieweke und die Expertise für Zellproduktion von Dr. Anke Fuchs am Zentrum für Regenerative Therapien Dresden (CRTD) der TU Dresden zusammen, um eine neuartige Immunzelltherapie gegen Krebs zu entwickeln und für die klinische Anwendung vorzubereiten. StemPhage ist eines von nur drei Projekten, die der EIC in Deutschland fördert und gehört zu den 40 ausgewählten Vorhaben aus insgesamt 611 europaweiten Anträgen.

Immunzellen als Krebskiller

Mit dem geplanten Startup EliaCell entwickelt ein Team am CRTD unter der Leitung von Prof. Michael Sieweke, Dr. Anke Fuchs und Dr. Angela Jacobi eine neue Form der Immuntherapie. Der Ansatz basiert auf Makrophagen – Immunzellen, die normalerweise im Körper Krankheitserreger erkennen und zerstören. Das Team am CRTD hat diese Zellen nun so modifiziert, dass sie Krebszellen effektiv und nachhaltig angreifen.

„Man kann sie sich als genetisch optimierte ‚Super-Makrophagen‘ vorstellen“, sagt Prof. Michael Sieweke, Alexander von Humboldt-Professor am CRTD. „Aufbauend auf jahrzehntelanger Forschung haben wir Makrophagen entwickelt, die sich in großem Maßstab vermehren lassen und in der Lage sind, solide Tumore nachhaltig zu bekämpfen.“

Herausforderung: Solide Tumore

Die Behandlung solider Tumore gilt nach wie vor als eine der größten Herausforderungen der Onkologie. Im Gegensatz zu Blut- und Lymphdrüsenkrebs bilden solide Tumore eine dichte Gewebemasse und machen etwa 90 Prozent aller Krebserkrankungen aus. Bei Blutkrebs wirksame Immunzell-Therapien scheitern bislang meist daran, effektiv in festes Tumorgewebe vorzudringen.

„Makrophagen dagegen können sehr gut in das Tumorgewebe eindringen, aber konventionelle Makrophagen konnte man bisher nicht in großen Mengen produzieren, und sie verlieren im Tumor schnell ihre Aktivität. Durch genetische Aktivierung konnten wir Makrophagen jetzt so stärken, dass sie sich vermehrt teilen, langfristig im Tumor bestehen und Krebszellen dauerhaft angreifen können“, erklärt Prof. Sieweke. „Unser Ziel ist es, damit neue Therapiemöglichkeiten für Patienten und Patientinnen mit bisher schlecht oder gar nicht behandelbaren soliden Tumoren zu eröffnen.“

Bezahlbare Spitzenmedizin

Die enormen Kosten von Zelltherapien machen bisher eine breite Anwendung in Gesundheitssystemen schwierig. Bisher war die Zelltherapie auf komplizierte Logistik und langwierige Prozesse angewiesen, um patienteneigene Zellen aufzubereiten. Ein neuer Ansatz soll das nun ändern. Durch ihre besondere Vermehrungsfähigkeit können EliaCell-Makrophagen in Arzneimittelqualität und in großen Mengen auf Vorrat hergestellt und dann bei Bedarf abgerufen werden. Therapien, die bisher auf hochspezialisierte Labore und wenige ausgewählte Kliniken angewiesen sind, sollten so perspektivisch breiter verfügbar werden.

„Unser Produktionsprozess erfüllt bereits die strengen Anforderungen für zellbasierte Therapien und ist so ausgelegt, dass er problemlos für die Massenproduktion skaliert werden kann“, erklärt Dr. Anke Fuchs, Forschungsgruppenleiterin für neuartige Therapien und wissenschaftliche Leiterin der Reinraum-Einrichtung für klinische Zellproduktion am CRTD.

Grundlagenforschung treibt Innovation

Das Projekt zeigt beispielhaft wie exzellente Grundlagenforschung klinischen Fortschritt und wirtschaftliche Wertschöpfung ermöglicht. StemPhage baut auf vorherigen Projekten von Prof. Michael Sieweke auf, die durch einen Advanced Grant und Proof-of-Concept Grant des European Research Council (ERC) gefördert wurden. Mit der neuen EIC-Transition-Förderung wird das Team nun eine Zelltherapie in klinischer Qualität entwickeln und eine erste klinische Studie vorbereiten.

„Die EIC-Förderung erlaubt uns den entscheidenden nächsten Schritt in Richtung der klinischen Translation“, sagt Dr. Angela Jacobi, Koordinatorin für StemPhage und treibende Kraft hinter dem geplanten Startup.

Das EliaCell-Team arbeitet zudem eng mit dem sächsischen Zukunftscluster für lebende Arzneimittel SaxoCell sowie mit klinischen Partnern wie Prof. Martin Bornhäuser (Medizinische Klinik I) und Prof. Martin Wermke (Early Clinical Trial Unit) am Universitätsklinikum Carl Gustav Carus Dresden zusammen. Die enge Verzahnung von wissenschaftlicher Expertise, Zellproduktions- und klinischem Studien-Know-how und die vorhandene Infrastruktur in Dresden bieten hervorragende Voraussetzungen für eine erfolgreiche Umsetzung des Projekts. Gemeinsam verfolgen die Partner das Ziel, Sachsen als führenden europäischen Innovationsstandort für zellbasierte Therapien zu etablieren.

„Als Europäer im Herzen Sachsens ist diese Förderung für EliaCell aber mehr als eine finanzielle Unterstützung: Sie bestätigt einen technologischen Ansatz, der in Europa einzigartig ist – und schafft die Voraussetzungen, aus einer exzellenten Innovation ein starkes, international wettbewerbsfähiges Unternehmen zu entwickeln,“ schließt Dr. Jacobi.

Über die EIC-Transition-Förderung

Der Europäische Innovationsrat (EIC) stärkt Europas technologische Souveränität, indem er bahnbrechende High-Tech-Innovationen auf dem Weg zum Markt unterstützt. Gefördert werden Projekte mit dem Potenzial, neue Technologiefelder zu prägen und Europas Wettbewerbsfähigkeit im globalen Innovationswettlauf zu sichern.

Mit bis zu 2,5 Millionen Euro werden Projekte unterstützt, die ihre Technologie in einer anwendungsrelevanten Umgebung validieren. Die ausgewählten Teams erhalten zudem Zugang zu den Business Acceleration Services des EIC, einschließlich Coaching und Mentoring, sowie die Möglichkeit eines Fast-Track-Zugangs zum EIC Accelerator für die spätere Kommerzialisierungsphase.

Über das Zentrum für Regenerative Therapien Dresden (CRTD)

Am Zentrum für Regenerative Therapien Dresden (CRTD) der TU Dresden widmen sich Spitzenforscher und -forscherinnen aus mehr als 30 Ländern neuen Therapieansätzen. Sie entschlüsseln die Prinzipien der Zell- und Geweberegeneration und ergründen deren Nutzung für Diagnose, Behandlung und Heilung von Krankheiten. Das CRTD verknüpft Labor und Klinik, vernetzt Wissenschaft und Klinik, nutzt Fachwissen in Stammzellforschung, Entwicklungs- und Regenerationsbiologie, um letztlich die Heilung von Erkrankungen wie Alzheimer und Parkinson, hämatologischen Krankheiten wie Leukämie, Stoffwechselerkrankungen wie Diabetes sowie Augen- und Knochenerkrankungen zu erreichen. Das CRTD wurde 2006 als Forschungszentrum der Deutschen Forschungsgemeinschaft (DFG) gegründet und bis 2018 als DFG-Forschungszentrum, sowie als Exzellenzcluster gefördert. Seit 2019 wird das CRTD mit Mitteln der TU Dresden und des Freistaates Sachsen finanziert.

Das CRTD ist eines von drei Instituten der zentralen wissenschaftlichen Einrichtung Center for Molecular and Cellular Bioengineering (CMCB) der TU Dresden.
www.tud.de/crtd
www.tud.de/cmcb

Ansprechpartnerin

Dr. Angela Jacobi
E-Mail: EliaCell@tu-dresden.de

LeapUp

LeapUp GmbH (formerly biosaxony Management GmbH) empowers founders, startups, and SMEs in the life sciences to take significant steps towards innovation, market entry, commercialization, and growth.

Their mission is to support scientists, companies and startups in the field of life sciences to transform their innovative ideas into scalable business models. Through their projects and world-class services, they help to bridge the gap between idea and realization. 

Their portfolio includes acceleration and development services for life science projects, regulatory support, training programs, and events through our in-house academy, as well as the provision of state-of-the-art co-working labs in Leipzig. They are actively expanding their international presence and service, including investor relations and funding opportunities.

Their focus areas include diagnostics, cell and gene therapy, radiopharmacy, smart medical devices, robotics and AI, digital health, and phage therapy.

Click here to visit their website.


hVIVO

hVIVO is a full-service early phase CRO offering end-to-end drug development services from preclinical consultancy through to Phase III clinical trials, including world leading end-to-end human challenge trials services. With decades of experience in rapidly delivering data for our global client base, our team brings together strategic insight and operational expertise to deliver a variety of clinical study types across multiple locations. 

To support rapid study start-up and reliable delivery, our dedicated recruitment teams in Germany and the UK provide direct access to both healthy volunteers and patient populations. This is complemented by our integrated drug development consultancy as well as our infectious disease and immunology laboratories and biobanking services.


Wirtschaftsförderung Sachsen GmbH

Saxony Trade & Invest Corporation (Wirtschaftsförderung Sachsen GmbH, WFS) is a state-owned economic development agency of the Free State of Saxony whose mission is to strengthen the region’s business and research environment. With more than 30 years of experience, the organization seeks to promote Saxony’s economy and support its stakeholders.

WFS acts on behalf of the state government, with its supervisory board chaired by the Saxony State Minister for Economic Affairs, Labor, Energy and Climate Protection.

The agency works in three specialist domains:

  • Foreign Trade & Fairs: supporting Saxon companies in connecting with international partners—customers, suppliers, or investors. 
  • Investor Services: assisting both domestic and foreign firms in establishing operations in Saxony or expanding existing ones. 
  • Industry, Innovation & Marketing: helping entrepreneurs and researchers focused on future technologies to find partners, develop projects, and access resources; also responsible for globally promoting Saxony as a business location. 

WFS offers a full suite of services: facilitating market entry, helping with company foundations or expansions, fostering networks between business and research, enabling cross-regional cooperation, and marketing the Saxony location internationally.

While based in Dresden, its remit extends across the entire state and beyond, aiming to support both local projects and international investment. The organization positions itself as a partner for companies, researchers, and investors with ideas, and offers tailored assistance for projects of all sizes.

Visit their website here.

https://business-saxony.com/en

Twist Bioscience

At Twist Bioscience, they work in service of customers who are changing the world for the better. In fields such as medicine, agriculture and industrial chemicals, by using their synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. The faster their customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to their customers. Their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about their products and services, please visit www.twistbioscience.com.

The future of CGT Leiden

On April 24, therapy developers from across the Cell and Gene Therapy space will meet in Leiden to share tools, cases, and hard-won lessons. Instead of lecture-like sessions, you can expect sharp discussions, hands-on workshops, and practical insights to help you develop better therapies, faster.

Whether you’re a biotech founder, platform innovator, investor, or clinician, this is your chance to connect, learn, and move the field forward, together.

In CGT, success isn’t just about innovation.
It’s about building the right company around it.
What to expect:

  • Case studies from real CGT projects, with lessons you can apply
  • Breakouts for biotech, manufacturing, regulatory, and clinical tracks
  • Workshops designed to build practical skills, not just spark ideas
  • A partnering setting that encourages honest conversations and new partnerships
  • A full-day program, all in one location, minutes from Leiden Central

You can check out their website here.

Qiagen


QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Their mission is to make improvements in life possible by enabling their customers to achieve outstanding success and breakthroughs in life sciences research, applied testing, pharma and molecular diagnostics. Further information can be found here.



FamiCord AG

FamiCord is Europe’s first and leading stem cell bank, trusted for decades and recognized for its strong clinical track record. We specialize in preserving perinatal cells and tissues and provide families across many countries with high‑quality, secure, and future‑oriented solutions. In Germany, Vita 34 in Leipzig has been FamiCord’s established market presence for 29 years. In addition to private customer services, FamiCord offers comprehensive services for business partners: We support third‑party companies with reliable and secure processing, testing, and long‑term storage of umbilical cord blood, cord tissue, and placenta tissue. With an extensive partner network across Europe, Asia, and Africa, we offer strong international coverage. We also provide specialized services for biotech companies and clinics and collaborate with academic institutions to advance regenerative medicine and biotechnology. Here Bramble Bio – a FamiCord company, supports pharmaceutical companies, biotech firms, hospitals, and academic institutions in developing and manufacturing innovative cell therapies. Services include process development for efficient and safe production workflows and cGMP‑compliant manufacturing to meet the highest clinical quality and safety standards.

Visit FamiCord’s website here.

Visit Vita 34’s website here.

You can view FamiCord’s image film below or by clicking here.

Sino Biological – Driving Discovery, Delivering Life-Changing Biotech Innovations

About Sino Biological

Sino Biological is a global leader in producing high-quality recombinant proteins, antibodies, and cDNA clones for life sciences, biotech, and pharmaceutical industries. With 15+ years of experience, we provide integrated solutions from research and development to full-scale manufacturing to accelerate scientific discovery and drug development.

Our Mission

Advance life science research and improve human health by delivering superior research reagents and contract research organization (CRO) services.

Core Competencies

– Recombinant Protein & Antibody Production: Custom research reagents supporting academic, biotech, and pharma innovation.  

– Pre-Clinical Production & CRO: Services supporting hundreds of monoclonal antibody drug candidates.  

– Bioprocess Center (USA): GMP-compliant facility specializing in low endotoxin production, high purity proteins, protein interaction analysis, tag removal, buffer screening, and glycosylation studies.

Innovation & Technology

Cutting-edge R&D platforms combined with scalable manufacturing ensure high-throughput, efficient production. Quality control includes biochemical, enzymatic, cellular, molecular, virological, and immunological assays.

Strategic Acquisition

In 2024, acquired SignalChem Biotech Inc., expanding our enzyme portfolio with the world’s largest active kinase catalog and enhanced enzyme assay development services.

Our People & Facilities

– 900+ staff, including 230+ with advanced degrees  

– 279,800 sq ft lab/office space  

– 75,000 sq ft GMP manufacturing facility  

– Global presence: Beijing HQ, subsidiaries in the US, Europe, Japan, and a worldwide distributor network

Clients

Serving academic institutions, biotech startups, and leading pharmaceutical companies worldwide.

Website: www.sinobiological.com

Sino Biological – Driving Discovery, Delivering Life-Changing Biotech Innovations

Check out Sino Biological’s image film by watching the video below or by clicking here

BioVaria

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising
start‑ups from across Europe. This unique event brings together Europe‘s leading tech transfer professionals, innovators from academia and start-ups with investors and representatives of
the global biotech and pharma industry.

• Scientists, technology transfer professionals, investors and industry scouts
• European technology transfer organizations presenting commercially
attractive licensable technologies and partnership opportunities
• Startup Pitch & Partner featuring some of Europe’s most promising
start‑ups
• Face-to-face discussions with investors and inventors.

BioVaria is Europe’s leading event for innovation in the life sciences. Organized by Ascenion and other European technology transfer companies, it brings together potential licensees and investors from the biotechnology and pharmaceutical industries with scientists, founders and technology transfer experts from all over Europe. On April 27 & 28, 2026, first-class research institutions, universities and university hospitals will present around 70 selected, licensable life science technologies. This year again, projects in early stages of
development will also be presented, including projects from Ascenion’s Life Science Digital Hub, which is funded by GO-Bio initial.

The Startup Pitch & Partner programme at BioVaria has been a special highlight for years: start-ups selected by a jury are given the opportunity to present their projects to international and regional investors and win prize money. Interested start-ups can apply for Startup Pitch & Partner until February 15, 2026.
Register now for BioVaria 2026!

More information at www.biovaria.org

 

Wirtschaftsförderung Sachsen GmbH

Saxony Trade & Invest Corporation (Wirtschaftsförderung Sachsen GmbH, WFS) is a state-owned economic development agency of the Free State of Saxony whose mission is to strengthen the region’s business and research environment. With more than 30 years of experience, the organization seeks to promote Saxony’s economy and support its stakeholders.

WFS acts on behalf of the state government, with its supervisory board chaired by the Saxony State Minister for Economic Affairs, Labor, Energy and Climate Protection.

The agency works in three specialist domains:

  • Foreign Trade & Fairs: supporting Saxon companies in connecting with international partners—customers, suppliers, or investors.
  • Investor Services: assisting both domestic and foreign firms in establishing operations in Saxony or expanding existing ones.
  • Industry, Innovation & Marketing: helping entrepreneurs and researchers focused on future technologies to find partners, develop projects, and access resources; also responsible for globally promoting Saxony as a business location.

WFS offers a full suite of services: facilitating market entry, helping with company foundations or expansions, fostering networks between business and research, enabling cross-regional cooperation, and marketing the Saxony location internationally.

While based in Dresden, its remit extends across the entire state and beyond, aiming to support both local projects and international investment. The organization positions itself as a partner for companies, researchers, and investors with ideas, and offers tailored assistance for projects of all sizes.

Click here to visit their website.

PROXIDRUGS

As part of Germany’s Clusters4Future initiative, PROXIDRUGS is being funded by the Federal Ministry of Research, Technology and Space since October 2021. The cluster focuses on developing new treatments for diseases with high unmet medical needs by utilizing the new concept of targeted protein degradation. Proximity-inducing drugs can trigger the degradation of disease-relevant proteins in a highly specific manner by directing them towards the cellular recycling system. That will open up new therapeutic options in a broad spectrum of diseases. It is assumed that 80% of proteins that are so far deemed as undruggable may be targeted by this strategy. 

PROXIDRUGS aims at improving this novel class of drugs in multiple ways: the strategy comprises the identification of suitable functional subunits for molecule engineering; the directed optimization of pharmacological properties; and the transfer to clinical phases. In line with this, the cluster interlinks currently 22 partners from academia and industry, covering the entire value chain from basic to translational research.

Click here to visit their website.

The National Network Office GCT

The National Network Office GCT Germany was established as part of the National Strategy for Gene and Cell-Based Therapies (GCT). The office is based at the Berlin Institute of Health (BIH) and operates independently in accordance with the mandate of the Federal Ministry of Education and Research (BMBF). Our mission is to build a national GCT community through independent information and networking, ensuring the inclusion of all stakeholder groups. Our stakeholders include representatives from science, industry, politics, and society, as well as authorities, foundations, and patient organizations.

We are consolidating and sharing knowledge: The GCT-Atlas serves as the central information platform and matchmaking hub, providing easy access to clinics, research networks and more. With GeneNovate, the first national entrepreneurship program in GCT, we provide the fundamentals of entrepreneurship, supporting researchers and physicians. Our growing community-based media portfolio includes the GCT newsletter, our LinkedIn channel and the upcoming media library.

Click here to visit their website.

 

biosaxony

biosaxony e.V. is the association of the biotechnology, medical technology and health economy sector in the region of Saxony. The members represent the various companies, research institutes and lobbyists working in biotechnology, medtech and the related areas of engineering and material sciences in Saxony. The cluster unites the different sectors of biotechnology and medical technology, identifies the needs of its members, and represents their interests at home and abroad.

biosaxony’s responsibilities include initiating projects between industry and research, pinpointing services and know-how, harnessing synergies, and highlighting regional expertise. Other elements of our cluster work include developing new ideas and strategies as well promoting sustainable technology transfer. The association’s office is in Dresden.

Click here to visit their website.

 

BioM

BioM has been the network organization of the biotechnology industry in Munich and Bavaria for over 25 years and operates as a non-profit organization on behalf of the Bavarian Ministry of Economic Affairs. BioM fosters a distinctive ecosystem in medical biotechnology, serving as a catalyst for innovation, growth and value creation. It interconnects stakeholders across Bavaria and identifies significant and sustainable trends.

In addition to providing tailored guidance for founders, we support selected Bavarian start-up teams from the life sciences and healthtech sectors with our incubator MAxL (Munich Accelerator Life Sciences & Medicine). MAxL offers high-end infrastructure, a structured incubation and coaching program as well as access to the extensive BioM network.

Moreover, BioM has been coordinating the m4 Award pre-seed competition in the field of biomedicine since 2011, which is funded by the Bavarian Ministry of Economic Affairs with a total of 2.5 million euros. To date, BioM has supported more than 250 start-ups. Besides organizing prominent events and network meetings, BioM offers a diverse range of training courses specifically tailored to meet the needs of stakeholders within the Bavarian Biotech Community.

Click here to visit their website.

 

bioRN Life Science Cluster

BioRN is the science and industry innovation cluster in the Rhine-Neckar region around Heidelberg, one of Germany’s strongest biotech and life science hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders.

The bioRN Life Science Cluster establishes initiatives to bridge the regional innovation stakeholders and to nurture and extend connections between members. It also fosters connections to other regions of innovation worldwide and stands for the promotion and visibility of the life science region at the national and international level.

The cluster acts as a neutral player, supporting cross-organizational programs and initiatives that advance the life science region as a whole. At the interface between academia and industry, bioRN provides translation support, especially by leveraging the unique combination of global pharma and leading academic institutions in the region.

Click here to visit their website.

LSX Leaders | London 2025 – SaxoCell at the Forefront of Life Sciences Innovation

LSX Leaders | London 2025 – SaxoCell at the Forefront of Life Sciences Innovation

Our transfer representative, Alexander Funkner, represented SaxoCell at the LSX Leaders Forum in London from April 28–30, 2025—one of Europe’s premier platforms for innovation, investment, and collaboration in the life sciences sector.

Under the motto “Accelerating European Life Sciences,” the forum brought together decision-makers, investors, and industry pioneers to explore emerging trends, pressing challenges, and the future of health innovation.

For SaxoCell, the conference provided valuable insights into:

  •  Strategic development of advanced cell and gene therapies
  • Effective transfer models for research and start-ups
  • New impulses for international partnerships and investments

A special highlight was the CEO Forum Day on April 28, which offered an exclusive environment for high-level exchange—an ideal platform to advance SaxoCell’s vision for a sustainable innovation and transfer culture.

Alongside compelling panels and keynotes, the forum also offered a chance for joyful reunions: Alexander reconnected with familiar faces from Wirtschaftsförderung Sachsen, leap up, and Apollo Health Ventures—a strong testament to Saxony’s dynamic presence and growing influence in the international life sciences arena.

SaxoCell Vor-Ort-Begehung

Am CRTD in Dresden war eine Expertenjury zu Gast, die unser Konzept zur Entwicklung innovativer Zell- und Gentherapien eingehend geprüft und bewertet hat.

Die Begutachtung durch das Bundesministerium für Bildung und Forschung und den Projektträger Jülich ist ein entscheidender Schritt in der Weiterentwicklung von SaxoCell. Eine positive Bewertung wäre nicht nur eine Bestätigung der wissenschaftlichen Exzellenz und Innovationskraft unseres Clusters, sondern würde auch den Weg für die nächste Phase der Förderung und Umsetzung ebnen.

Unser Team, bestehend aus erfahrenen Wissenschaftler:innn, Nachwuchskräften, Ärzt:innen und Industriepartnern, hat mit großem Engagement und Leidenschaft dafür gearbeitet, unser Cluster zu repräsentieren. Wir hatten großartige Projektpitches! Unsere PIs standen den Gutachtern Rede und Antwort! Hervorragende Poster verdeutlichten die Ziele und Potentiale unserer Projekte!

Wir bedanken uns bei allen Beteiligten für ihre harte Arbeit und ihre Unterstützung und blicken mit Zuversicht und Optimismus nach vorn. Gemeinsam hoffen wir auf eine positive Bewertung, die uns einen weiteren Schritt in Richtung eines Zell- und Gentherapie Leuchtturms in Sachsen bringt.